We hypothesized that treating a FOP patient with anti-IL-1 agents could help ameliorate the progression of this devastating disease, by slowing the rate of paroxysms, and/or limiting the symptoms and residual lesions. Here, IL1A is linked to fibrodysplasia ossificans progressiva.